阿卡波糖早期改善合并2型糖尿病的急性冠脉综合征患者的颈动脉斑块回声  

Early improvement in carotid plaque echogenicity by acarbose in patients with acute coronary syndromes

作　　者：肖辉[1] 陈冠瑶[1] 宁观林[1] 

机构地区：[1]广东省吴川市人民医院心血管内科,524500

出　　处：《中国现代药物应用》2014年第8期10-12,共3页Chinese Journal of Modern Drug Application

摘　　要：目的：对合并2型糖尿病（T2DM）的急性冠脉综合征（ACS）患者进行超声检查,评估颈动脉斑块回声增强,确定阿卡波糖是否可以迅速稳定不稳定的动脉斑块。方法连续性选入于2010年10月~2013年2月就诊于本院的合并T2DM的ACS患者且同时有颈动脉斑块的132例患者,将其随机分入阿卡波糖治疗组（150 or 300 mg/d, n=66）和对照组（n=66）。ACS患者于发病5 d内行阿卡波糖治疗。通过颈动脉超声以及整合背向散射技术测量斑块回声增强,评估不稳定的劲动脉斑块。治疗后2星期、1个月以及6个月内进行测量。整合背向散射指数（IBS）升高,说明颈动脉斑块回声增强。结果阿卡波糖治疗组, IBS在1个月内有显著升高,6个月内进一步升高,但对照组IBS只有少许变化。两组间差异有统计学意义（P〈0.05）。同时, IBS增高与C反应蛋白水平下降密切相关。结论阿卡波糖可以改善合并T2DM的ACS患者的颈动脉斑块回声的增强。Objective To evaluated carotid artery plaque echolucency using ultrasound in patients with ACS and type 2 diabetes mellitus （T2DM） to determine whether acarbose may rapidly stabilize unstable atherosclerotic plaques.Methods ACS patients with T2DM and carotid plaques （n=132） were randomly assigned to treatment with acarbose （150 or 300 mg/d, n=66） or a control group （no acarbose, n=66）. Acarbose treatment was initiated within 5 days after the onset of ACS. Unstable carotid plaques were assessed by measuring plaque echolucency using carotid ultrasound with integrated backscatter （IBS） before, and at 2 weeks, 1 month and 6 months after the initiation of treatment. An increase in the IBS value reflected an increase in carotid plaque echogenicity.Results IBS value of echolucent carotid plaques showed a significant increase at 1 month and a further increase at 6 months after treatment in the acarbose group, but there was minimal change in the control group. The increase in IBS values was significantly correlated with a decrease in C-reactive protein levels. Conclusion Acarbose rapidly improves carotid plaque echolucency within 1 month of therapy in patients with ACS and T2DM.

关 键 词：阿卡波糖 急性冠脉综合征 颈动脉斑块 2型糖尿病 超声 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]